Rivaroxaban (RIVA) is a selective, reversible, factor Xa inhibitor indicated in the treatment of atrial fibrillation (AF), coronary artery disease (CAD), indefinite anticoagulation peripheral artery disease (PAD), thromboprophylaxis, andvenous thromboembolism (VTE) and in reducing the risk of recurrent VTE, VTE prophylaxis in acutely ill medical patients, and VTE prophylaxis in total hip or knee arthroplasty [6]. The gene discussed is F10; the disease is atrial fibrillation.